对有妊娠期糖尿病风险的孕妇补充肌醇的临床与代谢结局:3项随机对照试验的二次分析
该研究为3项随机对照试验的二次分析,纳入595名有妊娠期糖尿病风险的孕妇,比较孕期全程补充肌醇(4 g/d)与对照组的临床与代谢结局。结果显示肌醇组妊娠期糖尿病诊断率、早产和巨大儿发生率均低于对照组,妊娠期高血压仅呈统计学趋势。
要点
- 肌醇组妊娠期糖尿病诊断率11.0%(32/291)低于对照组25.3%(77/304),P<.001。
- 肌醇组早产率3.4%(10/291)低于对照组7.6%(23/304),P=.03。
- 肌醇组巨大儿率2.1%(6/291)低于对照组5.3%(16/304),P=.04。
核心结论
- 对有妊娠期糖尿病风险的孕妇,早期妊娠开始补充肌醇与妊娠期糖尿病发生率、早产风险和巨大儿风险的降低相关。
研究设计与样本
- 3项随机对照试验数据库的二次分析,共纳入595名有妊娠期糖尿病风险的孕妇(父母一方患2型糖尿病、肥胖或超重)。
- 孕妇在整个孕期补充肌醇4 g/d。
主要发现
- 早产:肌醇组10/291(3.4%)vs 对照组23/304(7.6%),P=.03。
- 巨大儿(出生体重≥4000 g):肌醇组6/291(2.1%)vs 对照组16/304(5.3%),P=.04。
- 大于胎龄儿(胎儿生长≥90百分位):肌醇组14/291(4.8%)vs 对照组27/304(8.9%),P=.04。
- 妊娠期高血压:肌醇组4/291(1.4%)vs 对照组12/304(3.9%),P=.07,仅呈统计学趋势。
- 妊娠期糖尿病诊断:肌醇组32/291(11.0%)vs 对照组77/304(25.3%),P<.001。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gestational diabetes mellitus is defined as carbohydrate intolerance that begins or is first recognized during pregnancy. Insulin sensitizing substances such as myo-inositol have been considered for the prevention of gestational diabetes mellitus and related complications. OBJECTIVE: Because previous studies failed to show a clear reduction of gestational diabetes mellitus complications, the aim of this study was to evaluate clinical and metabolic outcomes in women who are at risk for gestational diabetes mellitus supplemented with myo-inositol since the first trimester. STUDY DESIGN: A secondary analysis of databases from 3 randomized, controlled trials (595 women enrolled) in which women who were at risk for gestational diabetes mellitus (a parent with type 2 diabetes mellitus, obese, or overweight) were supplemented with myo-inositol (4 g/d) throughout pregnancy. Main measures were the rate of adverse clinical outcomes: macrosomia (birthweight, ≥4000 g), large-for-gestational-age babies (fetal growth, ≥90 percentile), fetal growth restriction (fetal growth, ≤3 percentile), preterm birth (delivery before week 37 since the last menstruation), gestational hypertension, and gestational diabetes mellitus. RESULTS: A significant reduction was observed for preterm birth (10/291 [3.4%] vs 23/304 [7.6%]; P=.03), macrosomia (6/291 [2.1%] vs 16/304 [5.3%]; P=.04), Large-for-gestational-age babies (14/291 [4.8%] vs 27/304 [8.9%]; P=.04) with only a trend to significance for gestational hypertension (4/291 [1.4%] vs 12/304 [3.9%]; P=.07). Gestational diabetes mellitus diagnosis was also decreased when compared with the control group (32/291 [11.0%] vs 77/304 [25.3%]; P<.001). At univariate logistic regression analysis, myo-inositol treatment reduced the risk for preterm birth (odds ratio, 0.44; 95% confidence interval, 0.20-0.93), macrosomia (odds ratio, 0.38; 95% confidence interval, 0.14-0.98), and gestational diabetes mellitus diagnosis (odds ratio, 0.36; 95% confidence interval, 0.23-0.57). CONCLUSION: Myo-inositol treatment in early pregnancy is associated with a reduction in the rate of gestational diabetes mellitus and in the risk of preterm birth and macrosomia in women who are at risk for gestational diabetes mellitus.
引用
- Santamaria A, Alibrandi A, Di Benedetto A, et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. Am J Obstet Gynecol. 2018. PMID: 29859136. doi:10.1016/j.ajog.2018.05.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。